3Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from de American Heart Associa- tion Statistics Committee and Stroke Statistics Subcommittee [ J ]. Circulation, 2008, 117(4) :e25-146.
5Cour M, Gomez L, Mewton N, et al. Postconditioning: from the bench to bedside[J]. J Cardiovasc Pharmacol Ther, 2011, 16(2) :117-130.
6Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and transla- tional aspects of protective measures[ J]. Am J Physiol Heart Circ Physiol, 2011, '301 (5) :H1723-1741.
7Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs) : potential targets for the treatment of athero- sclerosis and vascular disease[ J]. Trends Pharmacol Sci, 2011, 32(3) :167-173.
8Frank A, Bonney M, Bonney S, et al. Myocardial ischemia reperfusion injury: from basic science to clinical bedside[ J]. Semin Cardiothorac Vasc Anesth, 2012, 16 (3) : 123-132.
9Dong M, Yan BP, Yu CM. Current status of rho-associated kina- ses (ROCKs) in coronary atherosclerosis and vasospasm [ J]. Cardiovasc Hematol Agents Med Chem, 2009, 7 (4) :322-330.
10Sharma V, Bell RM, Yellon DM. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury phar- macotherapy[ J ]. Expert Opin Pharmacother, 2012, 13 ( 8 ) : 1153-1175.
